title: Abnormal response to sodium channel blockers in patients with Brugada syndrome: augmented localised wall motion abnormalities in the right ventricular outflow tract region detected by electron beam computed tomography.
abstract: OBJECTIVE
  To investigate the relation between the wall motion abnormalities and sodium channel abnormalities in cases of the Brugada syndrome.
  
  
  METHODS
  Consecutive prospective case-control study in a single hospital.
  
  
  METHODS
  Tertiary referral centre.
  
  
  METHODS
  13 consecutive patients with Brugada syndrome and 13 age and sex matched control subjects.
  
  
  METHODS
  Each subject underwent electron beam computed tomography (EBT) and a 12 lead ECG before and after disopyramide injection.
  
  
  METHODS
  QRS width and the magnitude of ST segment elevation in the 12 lead ECG; wall motion by EBT.
  
  
  RESULTS
  After disopyramide, EBT revealed deterioration of focal wall motion abnormalities in the right ventricular outflow tract region in eight of the 13 patients (62%). Prolongation of the QRS width after disopyramide injection in lead V2, which usually reflects the electrical activity in right ventricular outflow tract region, was greater in these eight patients (p < 0.01) than in the other five patients, in whom wall motion did not change after disopyramide. The degree of augmentation of ST segment elevation did not differ significantly between the two groups
  
  
  CONCLUSIONS
  The deterioration of wall motion abnormalities in the right ventricular outflow tract region after disopyramide suggests the presence of functional abnormalities of the sodium channel. Some patients with Brugada syndrome may have arrhythmogenic substrates with abnormal responses to sodium channel blockers.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, National Cardiovascular Centre, Suita, Osaka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Takagi
authors.forename: N
authors.initials: N
authors.lastname: Aihara
authors.forename: S
authors.initials: S
authors.lastname: Kuribayashi
authors.forename: A
authors.initials: A
authors.lastname: Taguchi
authors.forename: T
authors.initials: T
authors.lastname: Kurita
authors.forename: K
authors.initials: K
authors.lastname: Suyama
authors.forename: S
authors.initials: S
authors.lastname: Kamakura
authors.forename: M
authors.initials: M
authors.lastname: Takamiya
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D002037:Bundle-Branch Block / Q000503:physiopathology*; D016022:Case-Control Studies; D004206:Disopyramide / Q000494:pharmacology*; D004562:Electrocardiography / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D026941:Sodium Channel Blockers / Q000494:pharmacology*; D013577:Syndrome; D014057:Tomography, X-Ray Computed; D018497:Ventricular Dysfunction, Right / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000503:physiopathology
chemical_list: D000889:Anti-Arrhythmia Agents; D026941:Sodium Channel Blockers; D004206:Disopyramide